Drug Type Monoclonal antibody |
Synonyms JABA, LY 2787106, LY2787106 |
Target |
Action inhibitors |
Mechanism Hepc inhibitors(Hepcidin inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | Phase 1 | United States | 01 Jan 2010 | |
Multiple Myeloma | Phase 1 | United States | 01 Jan 2010 | |
Solid tumor | Phase 1 | United States | 01 Jan 2010 |
Phase 1 | 33 | (Part A 0.3 mg/kg LY2787106) | lompvqrftz = wrcvocpkbp luhcfenxgn (pkbymypsyo, rfsbeljikc - ilkdluhfkg) View more | - | 03 Oct 2018 | ||
(Part A 1.0 mg/kg LY2787106) | lompvqrftz = lnfilpgkrh luhcfenxgn (pkbymypsyo, szgrloluuy - bruamyscfu) View more | ||||||
Phase 1 | 33 | gfghqdzkfq(fqvguyyjdl) = dose-dependent increase lbjwfharbo (rxvkeiejlr ) View more | Positive | 21 Mar 2017 |